Şunu aradınız:: trombolitiċi (Maltaca - İngilizce)

trombolitiċi
thrombolytics

eptifibatideu sustanzi trombolitiċi
eptifibatide and thrombolytic agents

eptifibatide u sustanzi trombolitiċi
eptifibatide and thrombolytic agents

antikoagulanti, antiplejtlits u trombolitiċi
anticoagulants, antiplatelets, and thrombolytics

metalyse jappartjeni għall-grupp ta’ mediċini msejħa sustanzi trombolitiċi.
metalyse belongs to a group of medicines called thrombolytic agents.

kura flimkien ma’ trombolitiċi (e.ż. rt-pa jew streptokinase) jistgħu
concomitant treatment with thrombolytics (e.g. rt-pa or streptokinase) may

dan l-avveniment ġie rrappurtat għall-klassi terapewtika ta’ sustanzi trombolitiċi.
this event has been reported for the therapeutic class of thrombolytic agents.

tagħrif dwar l-użu ta’ eptifibatide f’pazjenti li qed jirċievu sustanzi trombolitiċi huwa limitat.
data are limited on the use of eptifibatide in patients receiving thrombolytic agents.

l-aktar reazzjonijiet avversi gravi importanti kienu epatotossiċità u episodji ta’ trombolitiċi/tromboemboliċi.
the most important serious adverse reactions identified were hepatotoxicity and thrombotic/thromboembolic events.

esperjenza ta’ terapija kombinata ma’ aġenti trombolitiċi f’pazjenti b’hit tat-tip ii hija limitata ħafna.
experience of combined therapy with thrombolytic agents in patients with hit type ii is very limited.

bħal ma’ sustanzi trombolitiċi oħra dawn l-avvenimenti kardjovaskulari ġew irrappurtati bħala konsegwenza ta’ infart mijokardijaku u/jew amministrazzjoni trombolitika.
as with other thrombolytic agents these cardiovascular events have been reported as sequelae of myocardial infarction and/or thrombolytic administration.

l-użu flimkien ta’ desirudin ma’ trombolitiċi u ticlopidine ma kienx studjat f’dawn it-tipi ta’ pazjenti.
the concomitant use of desirudin with thrombolytics and ticlopidine has not been investigated in this patient population.

bħal sustanzi trombolitiċi oħrajn, l-avvenimenti li ġejjin kienu rrappurtati bħala konsegwenza ta’ infart mijokardjali u/jew ta’ għoti trombolitiku.
as with other thrombolytic agents, the following events have been reported as sequelae of myocardial infarction and/or thrombolytic administration:

l- inċidenza tad-dmija klinikament sinifikanti kienet simili għal dik osservata meta sustanzi trombolitiċi u heparin jingħataw flimkien ma’ asa (ara sezzjoni 4.8).
the incidence of clinically significant bleeding was similar to that observed when thrombolytic agents and heparin are co-administered with asa (see section 4.8)